Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Biocon history
Biocon company history timeline
2003 Biocon is the first company worldwide to develop human insulin on a Pichia expression system
Profits jumped more than 42 percent in 2003 alone.
In 2003 Jobs was diagnosed with a rare form of pancreatic cancer, and the following year he underwent a major reconstructive surgery known as the Whipple operation.
2004 Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.
In 2005 Mazumdar-Shaw also received the Padma Bhushan award, one of India’s highest civilian honours, for her pioneering work in industrial biotechnology.
He eventually sold the studio to the Disney Company in 2006.
Biocon and Neopharma signed an MOU in July of the year 2007 to establish Neobiocon a joint venture company in Dubai's biotechnology and research park Dubiotech.
As at January 2008 Biocon Limited and IATRICa Inc made a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases.
In February of the year 2008 the company had acquired 78% stake in German pharmaceutical company AxiCorp GmbH for a consideration of 30 million Euros.
As at June 2008 Biocon launched a Safety Device in the form of pre-filled syringes for two of its life saving products GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc.
Also during the year Biocon and HCG group of hospitals joined hands in fight against cervical.In 2010 Biocon and Bayer joined hands to create awareness for self monitoring for diabetics.
In August 2011 he resigned as CEO of Apple, and two months later, at age 56, he died.
In 2011 Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell Malaysia.
During the year Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp).In 2011 Biocon sold its stake in its German subsidiary AxiCorp GmbH to the existing group of promoter shareholders.
Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device 2012
In 2013 Biocon launched ALZUMAb- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India.
During the year Biocon expanded its Strategic Partnership with CytoSorbents to treat SIRS and Cardiac Surgery Patients.In 2015 Biocon commissioned Asia's largest integrated insulin manufacturing facility at the Biotech Park in Johor Malaysia.
Also during the year Biocon signed Co-Development & Commercialization Agreement with Lab PiSA for rh-Insulin in USA.In 2017 USFDA accepted Biologics License Application (BLA) for Mylan and Biocon's proposed Biosimilar Pegfilgrastim for review.
2019 Ogivri, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in Canada for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.
2020 Biocon Biologics approves a primary equity investment by True North, starting the value unlocking process for Biocon's biosimilars subsidiary.
Rate Biocon's efforts to communicate its history to employees.
Biocon jobs
Do you work at Biocon?
Does Biocon communicate its history to new hires?
Biocon competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Kadmon | 2009 | $8.3M | 101 | - |
| Dr. Reddy's Lab | 1984 | $2.1B | 75 | 14 |
| Incyte | 1991 | $4.2B | 1,600 | 40 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 190 |
| Axio Research | 1979 | $5.4M | 50 | 1 |
| Achillion Pharmaceuticals | 1998 | $15.0M | 56 | - |
| Zydus Pharmaceuticals | 2005 | $500.0M | 179 | 3 |
| Sun Pharmaceutical Industries Inc. | 1984 | $4.2B | 32,000 | 113 |
| BASi | 1974 | $23.5M | 421 | - |
Biocon history FAQs
Zippia gives an in-depth look into the details of Biocon, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Biocon. The employee data is based on information from people who have self-reported their past or current employments at Biocon. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Biocon. The data presented on this page does not represent the view of Biocon and its employees or that of Zippia.
Biocon may also be known as or be related to BIOCON INC, Biocon and Biocon Inc.